Total Payments
$99,851
2024 Payments
$33.07
Companies
9
Transactions
48
Medicare Patients
869
Medicare Billing
$186,011
Payment Breakdown by Category
Research$99,271 (99.4%)
Food & Beverage$536.40 (0.5%)
Other$43.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $99,271 | 39 | 99.4% |
| Food and Beverage | $536.40 | 8 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $43.36 | 1 | 0.0% |
Payments by Type
Research
$99,271
39 transactions
General
$579.76
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AI Therapeutics, Inc. | $91,016 | 4 | $0 (2021) |
| Astellas Pharma Global Development | $8,198 | 34 | $0 (2021) |
| Agios Pharmaceuticals, Inc. | $140.00 | 1 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $133.88 | 4 | $0 (2023) |
| Amgen Inc. | $116.08 | 1 | $0 (2018) |
| Kite Pharma, Inc. | $113.37 | 1 | $0 (2018) |
| AbbVie, Inc. | $57.03 | 1 | $0 (2019) |
| Servier Pharmaceuticals LLC | $43.36 | 1 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $33.07 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33.07 | 1 | SANOFI-AVENTIS U.S. LLC ($33.07) |
| 2023 | $100.90 | 3 | Pharmacyclics LLC, An AbbVie Company ($100.90) |
| 2022 | $32.98 | 1 | Pharmacyclics LLC, an AbbVie Company ($32.98) |
| 2021 | $15,425 | 4 | AI Therapeutics, Inc. ($15,187) |
| 2020 | $23,404 | 24 | AI Therapeutics, Inc. ($19,554) |
| 2019 | $44,416 | 12 | AI Therapeutics, Inc. ($40,064) |
| 2018 | $16,439 | 3 | AI Therapeutics, Inc. ($16,210) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $33.07 | General |
| Category: Oncology | ||||||
| 09/12/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $33.65 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $34.09 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $32.98 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2021 | AI Therapeutics, Inc. | — | — | Cash or cash equivalent | $15,187.40 | Research |
| Study: LAM-003-HEM-CLN02 | ||||||
| 07/26/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $94.58 | Research |
| Study: A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: ONCOLOGY | ||||||
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $43.36 | General |
| Category: ONCOLOGY | ||||||
| 01/20/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 09/18/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $449.58 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 09/18/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 07/28/2020 | AI Therapeutics, Inc. | — | — | Cash or cash equivalent | $19,554.20 | Research |
| Study: LAM-003-HEM-CLN02 | ||||||
| 07/09/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 07/09/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 06/15/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $23.75 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 06/15/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $22.35 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $427.21 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $70.83 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $53.13 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 04/21/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $427.71 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 03/17/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $151.66 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
| 03/17/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $140.00 | Research |
| Study: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LAM 003-HEM-CLN02 | AI Therapeutics, Inc. | $40,064 | 1 |
| LAM-003-HEM-CLN02 | AI Therapeutics, Inc. | $34,742 | 2 |
| LAM-003-HEM CLN02 | AI Therapeutics, Inc. | $16,210 | 1 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $4,154 | 9 |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Astellas Pharma Global Development | $3,849 | 23 |
| A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $194.58 | 2 |
| M15-531 | AbbVie, Inc. | $57.03 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 193 | 391 | $105,833 | $37,945 |
| 2022 | 6 | 211 | 454 | $113,996 | $40,979 |
| 2021 | 5 | 207 | 576 | $153,080 | $57,674 |
| 2020 | 10 | 258 | 579 | $146,557 | $49,413 |
Total Patients
869
Total Services
2,000
Medicare Billing
$186,011
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 141 | $34,412 | $14,244 | 41.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 49 | 104 | $27,232 | $7,862 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 52 | $18,640 | $6,122 | 32.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $13,080 | $4,416 | 33.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $5,856 | $2,523 | 43.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 26 | $4,188 | $1,746 | 41.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 15 | $2,425 | $1,031 | 42.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 68 | 187 | $41,888 | $15,713 | 37.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 35 | 105 | $32,970 | $11,439 | 34.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 95 | $22,135 | $7,199 | 32.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 24 | $10,464 | $4,025 | 38.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 30 | $4,680 | $1,810 | 38.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 13 | $1,859 | $793.41 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 56 | 214 | $67,196 | $24,811 | 36.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 64 | 232 | $51,968 | $20,368 | 39.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 68 | $15,844 | $5,643 | 35.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 28 | 30 | $13,080 | $4,883 | 37.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 32 | $4,992 | $1,969 | 39.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 55 | 202 | $63,428 | $17,755 | 28.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 40 | 161 | $36,064 | $14,526 | 40.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 42 | 64 | $14,912 | $3,707 | 24.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 21 | $9,156 | $3,695 | 40.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 21 | 42 | $6,552 | $2,589 | 39.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $6,735 | $2,207 | 32.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 17 | 18 | $4,230 | $2,016 | 47.7% |
About Dr. Maria Baer, MD
Dr. Maria Baer, MD is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1700881802.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Maria Baer, MD has received a total of $99,851 in payments from pharmaceutical and medical device companies, with $33.07 received in 2024. These payments were reported across 48 transactions from 9 companies. The most common payment nature is "" ($99,271).
As a Medicare-enrolled provider, Baer has provided services to 869 Medicare beneficiaries, totaling 2,000 services with total Medicare billing of $186,011. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 06/15/2005
- Last Updated 09/06/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700881802
Products in Payments
- XOSPATA (Drug) $8,198
- TIBSOVO (Drug) $183.36
- Kyprolis (Biological) $116.08
- IMBRUVICA (Drug) $67.07
- EPKINLY (Drug) $66.81
- Venclexta (Drug) $57.03
- REZUROCK (Drug) $33.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816